Cesar Vega Quintana | Universidad Nacional José Faustino Sánchez Carrión (original) (raw)
Uploads
Papers by Cesar Vega Quintana
Journal of Invertebrate Pathology
Objective: To present our experience in the diagnosis and intravascular treatment of cerebral pse... more Objective: To present our experience in the diagnosis and intravascular treatment of cerebral pseudoaneurysms. Material and methods: We present 11 pseudoaneurysms (2 traumatic, 2 mycotic, 3 iatrogenic, and 4 with other causes). We analyze the methods and diagnostic criteria, radiological and clinical outcome, the criteria used in making decisions about treatment, the method of treatment, and the complications. Results: Digital subtraction angiography is the gold standard for the diagnosis of cerebral pseudoaneurysms; the diagnostic criteria in the literature include: aneurysms with early morphological changes and distal aneurysms or proximal aneurysms associated with another distal one, in the context of the right symptoms and signs. In the nine patients treated with endovascular techniques, the treatment objective was achieved and rebleeding did not occur. Conclusions: In cases with clinical suspicion of a pseudoaneurysm, the patient should undergo angiography. This is especially important in patients with inexplicable cerebral hemorrhage and in those with septicemia. CT angiography and MR angiography have good diagnostic accuracy and can replace conventional angiography. However, the treatment of choice is endovascular and treatment should not be delayed unless access to the pseudoaneurysm is impeded, usually due to severe cerebral vasospasm. Documento descargado de http://www.elsevier.es el 26/07/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
In this paper we analyse three different techniques to establish an optimal-cost class threshold ... more In this paper we analyse three different techniques to establish an optimal-cost class threshold when training data is not available. One technique is directly derived from the definition of cost, a second one is derived from a ranking of estimated probabilities and the third one is based on ROC analysis. We analyse the approaches theoretically and experimentally, applied to the adaptation of existing models. The results show that the techniques we present are better for reducing the overall cost than the classical approaches (e.g. oversampling) and show that cost contextualisation can be performed with good results when no data is available.
American Journal of Medicine, 2001
To describe 2 cases of parvovirus B19 (B19) infection mimicking systemic lupus erythematosus (SLE... more To describe 2 cases of parvovirus B19 (B19) infection mimicking systemic lupus erythematosus (SLE) and to identify all cases of SLE imitated by and/or associated with B19 in the medical literature. A computer-assisted (PubMed) search of the medical literature from 1975 to 2003 was performed using the following key words: parvovirus, B19, SLE, lupus, antibodies, auto-immunity. Thirty-eight patients were identified: 35 women, 3 men; mean age = 28.8 years. Clinical manifestations were as follows: fever (24 patients); articular involvement (36 patients); cutaneous lesions (28 patients); lymphadenopathy (9 patients); hepato- and/or splenomegaly (6 patients); serositis (6 patients); renal involvement (4 patients); cerebral impairment (10 patients). Cytopenia was observed in 23 cases. Antinuclear antibodies were detected in 34 patients, anti-double-stranded DNA antibodies in 20 patients, anti-Sm antibodies in 4 patients, antinuclear ribonucleoprotein antibodies in 5 patients, anti-Ro-SSA antibodies in 4 patients, anti-La-SSB antibodies in 4 patients, and anticardiolipin and/or anti-beta2-glycoprotein I antibodies in 8 patients. Hypocomplementemia was found in 15 of 26 patients. In 19 cases, the B19 infection had a self-limiting course. In 6 cases, B19 infection occurred in a context of previously established SLE, simulating SLE exacerbation. In 6 observations, symptoms persisted several months after the viral infection. In 7 cases, the exact relationship between SLE and B19 could not be determined. B19 infection may present a clinical and serological tableau making it difficult to distinguish between a viral infection and the first episode of SLE. Although B19 may modulate the clinical and biological features of rheumatic disease, studies in large series do not support a causative role for B19 in the pathogenesis of SLE.
Currently, there are no effective tools to fight multiple pathogens due to the insufficient knowl... more Currently, there are no effective tools to fight multiple pathogens due to the insufficient knowledge on their components and the limited arsenal of vaccine alternatives. In the present paper, combinations of recombinant viral antigens and nucleic acids are studied using electron microscopy, electrophoresis, nuclease digestion and sucrose or cesium chloride gradients. We describe new data on morphology, size, and the
European Neuropsychopharmacology, 2009
In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the... more In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS). Because Peru was the first country in the Americas to adopt this combination therapy, we established a surveillance system in the region to assess the frequency of new or worsening symptoms after starting therapy. Over a period of two years, 1,552, or approximately two-thirds of all patients with uncomplicated P. falciparum malaria who had received SP-AS on the northern coast were followed up. Of these, 8.8% reported at least one adverse effect, with the most common being vomiting, nausea, headache, abdominal pain, dizziness, and fever; no severe adverse effects related to SP-AS therapy were identified. Treatment of uncomplicated malaria with SP-AS was associated with a low frequency of mild adverse effects in Peru, and therefore should be considered as a first-line therapy in areas of the Americas where SP efficacy is still high.
Journal of Invertebrate Pathology
Objective: To present our experience in the diagnosis and intravascular treatment of cerebral pse... more Objective: To present our experience in the diagnosis and intravascular treatment of cerebral pseudoaneurysms. Material and methods: We present 11 pseudoaneurysms (2 traumatic, 2 mycotic, 3 iatrogenic, and 4 with other causes). We analyze the methods and diagnostic criteria, radiological and clinical outcome, the criteria used in making decisions about treatment, the method of treatment, and the complications. Results: Digital subtraction angiography is the gold standard for the diagnosis of cerebral pseudoaneurysms; the diagnostic criteria in the literature include: aneurysms with early morphological changes and distal aneurysms or proximal aneurysms associated with another distal one, in the context of the right symptoms and signs. In the nine patients treated with endovascular techniques, the treatment objective was achieved and rebleeding did not occur. Conclusions: In cases with clinical suspicion of a pseudoaneurysm, the patient should undergo angiography. This is especially important in patients with inexplicable cerebral hemorrhage and in those with septicemia. CT angiography and MR angiography have good diagnostic accuracy and can replace conventional angiography. However, the treatment of choice is endovascular and treatment should not be delayed unless access to the pseudoaneurysm is impeded, usually due to severe cerebral vasospasm. Documento descargado de http://www.elsevier.es el 26/07/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
In this paper we analyse three different techniques to establish an optimal-cost class threshold ... more In this paper we analyse three different techniques to establish an optimal-cost class threshold when training data is not available. One technique is directly derived from the definition of cost, a second one is derived from a ranking of estimated probabilities and the third one is based on ROC analysis. We analyse the approaches theoretically and experimentally, applied to the adaptation of existing models. The results show that the techniques we present are better for reducing the overall cost than the classical approaches (e.g. oversampling) and show that cost contextualisation can be performed with good results when no data is available.
American Journal of Medicine, 2001
To describe 2 cases of parvovirus B19 (B19) infection mimicking systemic lupus erythematosus (SLE... more To describe 2 cases of parvovirus B19 (B19) infection mimicking systemic lupus erythematosus (SLE) and to identify all cases of SLE imitated by and/or associated with B19 in the medical literature. A computer-assisted (PubMed) search of the medical literature from 1975 to 2003 was performed using the following key words: parvovirus, B19, SLE, lupus, antibodies, auto-immunity. Thirty-eight patients were identified: 35 women, 3 men; mean age = 28.8 years. Clinical manifestations were as follows: fever (24 patients); articular involvement (36 patients); cutaneous lesions (28 patients); lymphadenopathy (9 patients); hepato- and/or splenomegaly (6 patients); serositis (6 patients); renal involvement (4 patients); cerebral impairment (10 patients). Cytopenia was observed in 23 cases. Antinuclear antibodies were detected in 34 patients, anti-double-stranded DNA antibodies in 20 patients, anti-Sm antibodies in 4 patients, antinuclear ribonucleoprotein antibodies in 5 patients, anti-Ro-SSA antibodies in 4 patients, anti-La-SSB antibodies in 4 patients, and anticardiolipin and/or anti-beta2-glycoprotein I antibodies in 8 patients. Hypocomplementemia was found in 15 of 26 patients. In 19 cases, the B19 infection had a self-limiting course. In 6 cases, B19 infection occurred in a context of previously established SLE, simulating SLE exacerbation. In 6 observations, symptoms persisted several months after the viral infection. In 7 cases, the exact relationship between SLE and B19 could not be determined. B19 infection may present a clinical and serological tableau making it difficult to distinguish between a viral infection and the first episode of SLE. Although B19 may modulate the clinical and biological features of rheumatic disease, studies in large series do not support a causative role for B19 in the pathogenesis of SLE.
Currently, there are no effective tools to fight multiple pathogens due to the insufficient knowl... more Currently, there are no effective tools to fight multiple pathogens due to the insufficient knowledge on their components and the limited arsenal of vaccine alternatives. In the present paper, combinations of recombinant viral antigens and nucleic acids are studied using electron microscopy, electrophoresis, nuclease digestion and sucrose or cesium chloride gradients. We describe new data on morphology, size, and the
European Neuropsychopharmacology, 2009
In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the... more In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS). Because Peru was the first country in the Americas to adopt this combination therapy, we established a surveillance system in the region to assess the frequency of new or worsening symptoms after starting therapy. Over a period of two years, 1,552, or approximately two-thirds of all patients with uncomplicated P. falciparum malaria who had received SP-AS on the northern coast were followed up. Of these, 8.8% reported at least one adverse effect, with the most common being vomiting, nausea, headache, abdominal pain, dizziness, and fever; no severe adverse effects related to SP-AS therapy were identified. Treatment of uncomplicated malaria with SP-AS was associated with a low frequency of mild adverse effects in Peru, and therefore should be considered as a first-line therapy in areas of the Americas where SP efficacy is still high.